Last $1.61 USD
Change Today -0.10 / -5.85%
Volume 517.1K
NAVB On Other Exchanges
NAVB is not on other exchanges.
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

navidea biopharmaceuticals i (NAVB) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $2.12
52 Week Low
11/12/14 - $0.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

navidea biopharmaceuticals i (NAVB) Related Businessweek News

View More BusinessWeek News

navidea biopharmaceuticals i (NAVB) Details

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in lymphatic mapping procedures, which are performed to evaluate breast cancer and melanoma; Manocept platform to target the CD206 mannose receptor expressed on macrophages; and NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia; and NAV1800, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

57 Employees
Last Reported Date: 03/14/14
Founded in 1983

navidea biopharmaceuticals i (NAVB) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $274.7K
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: $334.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $300.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $276.4K
Compensation as of Fiscal Year 2013.

navidea biopharmaceuticals i (NAVB) Key Developments

Navidea Biopharmaceuticals, Inc Announces Management Changes

Navidea Biopharmaceuticals Inc. announced that it has appointed Thomas J. Klima as Senior Vice President and Chief Commercial Officer and Michael Tomblyn, M.D., M.S. as Executive Medical Director. These additions to the company's team are being made to support the continued emphasis on the growth of Lymphoseek® (technetium Tc 99m tilmanocept) injection. Thomas J. Klima joins Navidea having held numerous commercial leadership positions, including Head of Sales for oncology company, Algeta (recently acquired by Bayer AG) and Senior Director of Marketing at Dendreon Corporation. Mr. Klima also led various U.S. and global commercial efforts at Eli Lilly, including U.S. Marketing for the Cymbalta Brand Team. Michael Tomblyn, M.D., M.S. served as Senior Medical Director of Bayer Healthcare/Algeta focusing on targeted-radiation therapies. Prior to this Dr. Tomblyn was Assistant Member and Director of Clinical Research, Department of Radiation Oncology, at H. Lee Moffitt Cancer Center and Assistant Professor, Department of Oncologic Science, at University of South Florida.

Navidea Biopharmaceuticals, Inc Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 02:30 PM

Navidea Biopharmaceuticals, Inc Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 02:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Navidea Biopharmaceuticals Establishes New Business Unit, Macrophage Therapeutics

Navidea Biopharmaceuticals has established a new business unit, Macrophage Therapeutics. The new business unit is to further explore therapeutic applications for the Manocept platform, which serves as the molecular backbone of Navidea's FDA-approved, activated macrophage-targeting agent, Lymphoseek (technetium Tc 99m tilmanocept) injection. The company aims to structure Macrophage Therapeutics such that it will remain under Navidea's control, allowing present shareholders to capture potential future value, but also allow funding of future development in a standalone, non-dilutive manner to Navidea's present shareholders.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVB:US $1.61 USD -0.10

NAVB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $21.42 USD -0.53
CTI BioPharma Corp $2.20 USD +0.03
Curis Inc $1.84 USD -0.02
Exact Sciences Corp $27.21 USD -0.81
Infinity Pharmaceuticals Inc $15.44 USD +0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation NAVB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 43.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVIDEA BIOPHARMACEUTICALS I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at